GlobeNewswire Inc | Oct 1, 2021 08:00AM EDT

October 01, 2021

CAMBRIDGE, Mass., Oct. 01, 2021 (GLOBE NEWSWIRE) -- Codiak BioSciences, Inc. (Nasdaq: CDAK), a clinical-stage biopharmaceutical company focused on pioneering the development of exosome-based therapeutics as a new class of medicines, today announced that three posters featuring preclinical data from its engEx Platform programs will be presented during the 36th Annual Meeting of the Society for Immunotherapy of Cancer (SITC 2021), which is being held virtually and in person in Washington, D.C. from November 10-14, 2021.

In addition, Codiaks Chief Scientific Officer, Sriram Sathyanarayanan, Ph.D., will co-chair a session entitled Exosomes and Cellular Engineering and present on the companys approach to developing engineered exosome therapeutics and the opportunity to overcome historical challenges of other modalities in immuno-oncology.

At SITC this year, we will present for the first time preclinical data on our exosome therapeutic candidates in two new settings, including in leptomeningeal disease with exoSTING and in combination therapy with exoSTING and exoIL-12 in solid tumors, said Dr. Sathyanarayanan. In addition, we will share new data in hepatocellular carcinoma models with our next clinical candidate, exoASO-STAT6, for which we expect to file an IND by the end of the year. Taken together, these data point to new potential therapeutic applications for engineered exosomes and the flexibility and broad potential of our platform to create new classes of molecular medicines.

Poster Presentations:exoSTING Demonstrates Potent Anti-Tumor Activity in a Mouse Model of Leptomeningeal DiseaseAbstract number: 761Date: Friday, November 12, 2021

Exosome-Mediated Reprogramming of Tumor-Associated Macrophages by exoASO-STAT6 for the Treatment of Hepatocellular Carcinoma (HCC)Abstract number: 842Date: Saturday, November 13, 2021

Combination Therapy of exoSTING, exoIL-12 Activates Systemic Anti-Tumor ImmunityAbstract number: 572Date: Saturday, November 13, 2021

Abstracts will be made available by SITC on November 9, 2021 at 8:00 a.m. ET and posters will be available via the conference platform beginning November 12, 2021 at 7:00 a.m. ET.

Concurrent Session:Exosomes and Cellular Engineering (#216)Title: Developing Engineered Exosome Based Therapeutics for Immuno-OncologyDate/Time: Saturday, November 13, 2021, 5:10-6:25 p.m. ET

About the engEx PlatformCodiaks proprietary engEx Platform is designed to enable the development of engineered exosome therapeutics for a wide spectrum of diseases andto manufacturethem reproducibly and at scale to pharmaceutical standards. By leveraging the inherent biology, function and tolerability profile of exosomes, Codiak is developing engEx exosomes designed to carry and protect potent drug molecules, provide selective delivery and elicit the desired pharmacology at the desired tissue and cellular sites. Through its engEx Platform, Codiak seeks to direct tropism and distribution by engineering exosomes to carry on their surface specific targeting drug moieties, such as proteins, antibodies/fragments, and peptides, individually or in combination. Codiak scientists have identified two exosomal proteins that serve as surface and luminal scaffolds. By engineering the exosome surface or lumen and optimizing the route of administration, Codiak aims to deliver engEx exosomesto the desired cell and tissue to more selectively engage the drug target, potentially enhancing the therapeutic index by improving potency and reducing toxicity.

About Codiak BioSciences Codiak is a clinical-stage biopharmaceutical company focused on pioneering the development of exosome-based therapeutics, a new class of medicines with the potential to transform the treatment of a wide spectrum of diseases with high unmet medical need. By leveraging the biology of exosomes as natural intercellular transfer mechanisms, Codiak has developed its proprietary engEx Platform to expand upon the innate properties of exosomes to design, engineer and manufacture novel exosome therapeutic candidates. Codiak has utilized its engEx Platform to generate a deep pipeline of engineered exosomes aimed at treating a broad range of disease areas, spanning oncology, neuro-oncology, neurology, neuromuscular disease and infectious disease.

Forward-Looking StatementsThis press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, among other things, statements concerning the development and therapeutic potential of exoIL-12 and exoASO-STAT6, including future development plans and regulatory filings and timing with respect thereto. Any forward-looking statements in this press release are based on managements current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. For a discussion of these risks and uncertainties, and other important factors, any of which could cause our actual results to differ from those contained in the forward-looking statements, see the section entitled Risk Factors in Codiaks Annual Report on Form10-Kfor the year ended December31, 2020, and in subsequent filings with the Securities and Exchange Commission, as well as discussions of potential risks, uncertainties and other important factors in Codiaks subsequent filings with the Securities and Exchange Commission. All information in this press release is current as of the date of this report, and Codiak undertakes no duty to update this information unless required by law.

Investor Contact:Christopher TaylorVP, Investor Relations and Corporate CommunicationsT: 617-949-4220E: investor@codiakbio.com

Media Contact:Lindy DevereuxScient PRT: 646-515-5730E: media@codiakbio.com